Evidence map›Paper›PMID 26950487›Full record

ArticleLaboratory investigation; a journal of technical methods and pathology2016

PIK3C2A is a gene-specific target of microRNA-518a-5p in imatinib mesylate-resistant gastrointestinal stromal tumor.

Yuan Shi, Xiaodong Gao, Qin Hu, Xiaojing Li, Jianfang Xu, Shaohua Lu, Yalan Liu, Chen Xu, Dongxian Jiang, Jiaqian Lin and 4 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Laboratory investigation; a journal of technical methods and pathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Noncoding RNAs in Drug Resistance of Gastrointestinal Stromal Tumor.Frontiers in cell and developmental biology · 2022
    Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Molecular biomarkers for prognosis of gastrointestinal stromal tumor.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Yuan ShiDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Xiaodong GaoDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Qin HuDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Xiaojing LiDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Jianfang XuDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Shaohua LuDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yalan LiuDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Chen XuDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Dongxian JiangDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Jiaqian LinDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Anwei XueDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Yunshan TanDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Kuntang ShenDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Yingyong HouDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Sun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Imatinib mesylate resistance occurs in some patients with gastrointestinal stromal tumors (GISTs) during the course of treatment. In this study, we investigated the relationship between microRNAs (miRNAs) and imatinib-resistant GISTs, and the effect of miR-518a-5p on PIK3C2A in imatinib-resistant GISTs. A total of 20 matched-pair GIST samples from imatinib-resistant patients were included in the study. Each of the paired tumor specimens were from the same patient who had surgical removal of GISTs preimatinib and postimatinib treatment. Seven pairs of tissues were resected for microarray analysis, and the remaining 13 pairs were utilized for miRNAs analysis. Target genes were selected based on bioinformatics from multiple biological databases. Luciferase reporter assays were used to confirm the binding of miR-518a-5p to PIK3C2A 3'UTR. GIST882R-NC, 882R-miR-518a-5p-OE, and 882R-miR-518a-5p-KD cell lines were constructed using lentiviral vectors. miR-518a-5p and PIK3C2A expression in 882R-NC, 882R-OE, and 882R-KD cells was assessed by real-time PCR and western blotting. A cell counting kit was used to detect the influence of miR-518a-5p to cell proliferation. TUNEL staining was applied to detect the influence of miR-518a-5p to cell apoptosis. Microarray analysis showed that miR-518a-5p was downregulated in imatinib-resistant GISTs, and the expression of miR-518a-5p was confirmed with good concordance between real-time PCR and miRNA microarray results. Luciferase reporter assays indicated that miR-518a-5p bound to the PIK3C2A 3'UTR. Compared with 882R-OE, PIK3C2A expression was significantly increased in 882R-KD cells. MiR-518a-5p reduced 882R proliferation and promoted 882R apoptosis. In conclusion, PIK3C2A is a gene-specific target of miR-518a-5p in imatinib mesylate-resistant GISTs. Low expression of miR-518a-5p is likely to upregulate PIK3C2A and affect the cellular response to the drug, causing resistance to imatinib in GISTs.

Indexed as

3' Untranslated RegionsAdultAgedAntineoplastic AgentsApoptosisCell Line, TumorCell ProliferationDown-RegulationDrug Resistance, NeoplasmFemaleGastrointestinal NeoplasmsGastrointestinal Stromal TumorsGene Expression Regulation, NeoplasticHEK293 CellsHumansImatinib Mesylate3' Untranslated RegionsAntineoplastic AgentsImatinib MesylateMicroRNAsMIRN518 microRNA, humanPhosphatidylinositol 3-KinasesPIK3C2A protein, humanProtein Kinase InhibitorsRNA, Neoplasm

Identifiers

PMID26950487
OpenAlexW2301120951

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.